Do-Youn Oh
吴度允
MD, PhD
Professor, Department of Internal Medicine (Medical Oncology)内科（肿瘤内科）教授
👥Biography 个人简介
Internationally acclaimed biliary tract cancer specialist who led the pivotal TOPAZ-1 trial establishing durvalumab plus chemotherapy as the new first-line standard for advanced biliary tract cancer. Key contributor to multiple pan-GI immunotherapy trials. Instrumental in advancing precision medicine in rare GI cancers in Asia.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Biliary Tract Cancer Immunotherapy
Principal investigator of TOPAZ-1, demonstrating durvalumab plus gemcitabine/cisplatin improves OS in advanced BTC, leading to first immunotherapy approval in biliary tract cancer globally.
Precision Oncology in GI Cancers
Conducted biomarker-driven analyses identifying predictors of immunotherapy response across biliary, gastric, and pancreatic cancers in Asian patient populations.
Representative Works 代表性著作
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1)
NEJM Evidence (2022)
Pivotal trial establishing durvalumab+gemcitabine/cisplatin as new first-line standard for advanced biliary tract cancer.
A phase Ib study of durvalumab plus tremelimumab in patients with advanced biliary tract cancer
Journal of Hepatology (2021)
Demonstrated dual checkpoint blockade activity in biliary tract cancer, informing combination strategies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 吴度允 的研究动态
Follow Do-Youn Oh's research updates
留下邮箱，当我们发布与 Do-Youn Oh（Seoul National University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment